Revvity (RVTY)
NYSE: RVTY · Health Care Equipment · Waltham, MA
Our rating: Neutral
Neutral reaffirmed at $158.25, moderate conviction, November 11, 2026.
Breaks if: Neutral turns Cautious if revenue growth decelerates to below 2% in any two of the next three quarterly filings, or if trailing twelve-month free cash flow drops below $400M — either would signal the recovery thesis is stalling faster than the multiple can absorb. Neutral turns Positive if revenue growth prints above 8% for two consecutive quarters while net margin expands above 12%, demonstrating that earnings power is genuinely catching up to the valuation.
Key figures
| Market value | $16.2B |
|---|---|
| Revenue, last 12 months | $2.9B |
| Net income, last 12 months | $253M |
| Free cash flow, last 12 months | $590M |
| Price to earnings | 64.0× |
| Free cash flow yield | 3.6% |
| Dividend yield | 0.2% |
| Operating margin | 12.6% |
| Return on equity | 3.5% |
| Beta to the S&P 500 | 1.07 |
| Volatility, annualized | 37.2% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| October 4, 2026 | $729M | 4.3% | $0.56 | $152M |
| July 5, 2026 | $730M | 1.3% | $0.47 | $181M |
| April 5, 2026 | $711M | 7.0% | $0.36 | $95M |
| December 28, 2025 | $772M | 5.9% | $0.86 | $162M |
| September 28, 2025 | $699M | 2.2% | $0.40 | $120M |
| June 29, 2025 | $720M | 4.1% | $0.46 | $115M |
| March 30, 2025 | $665M | 2.3% | $0.35 | $112M |
| December 29, 2024 | $729M | 4.8% | $0.78 | $150M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.81B: Claude 42%, Gemini 75%, Mistral 28%
- Diluted earnings per share are at least $0.86: Claude 45%, Gemini 75%, Mistral 32%
- Free cash flow for the quarter is at least $0.16B: Claude 52%, Gemini 65%, Mistral 42%
15 ledger entries and 47 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.